Michel Sadelain
#88,651
Most Influential Person Now
American immunologist
Michel Sadelain's AcademicInfluence.com Rankings
Michel Sadelainbiology Degrees
Biology
#4267
World Rank
#6388
Historical Rank
Immunology
#200
World Rank
#209
Historical Rank
Download Badge
Biology
Michel Sadelain's Degrees
- Doctorate Medicine Paris Diderot University
- PhD Immunology Paris Diderot University
Why Is Michel Sadelain Influential?
(Suggest an Edit or Addition)According to Wikipedia, Michel Sadelain is an genetic engineer and cell therapist at Memorial Sloan Kettering Cancer Center, New York, New York, where he holds the Steve and Barbara Friedman Chair. He is the founding director of the Center for Cell Engineering and the head of the Gene Transfer and Gene Expression Laboratory. He is a member of the department of medicine at Memorial Hospital and of the immunology program at the Sloan Kettering Institute. He is best known for his major contributions to T cell engineering and chimeric antigen receptor therapy, an immunotherapy based on the genetic engineering of a patient's own T cells to treat cancer.
Michel Sadelain's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling (2009) (3011)
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia (2014) (2022)
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia (2013) (1766)
- Long‐Term Follow‐up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia (2018) (1466)
- Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. (2011) (1159)
- Chimeric Antigen Receptor Therapy. (2018) (1122)
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection (2017) (1121)
- The basic principles of chimeric antigen receptor design. (2013) (1026)
- Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis. (1994) (890)
- Modeling Pathogenesis and Treatment of Familial Dysautonomia using Patient Specific iPSCs (2009) (862)
- Gene therapy comes of age (2018) (769)
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade (2018) (715)
- Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells (2012) (712)
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. (2016) (649)
- Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ /CD28 receptor (2002) (623)
- Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 (2003) (599)
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells. (2015) (567)
- PD-1– and CTLA-4–Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses (2013) (548)
- Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. (2012) (534)
- Therapeutic T cell engineering (2017) (527)
- Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin (2000) (507)
- Targeting tumours with genetically enhanced T lymphocytes (2003) (495)
- Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. (2018) (470)
- The promise and potential pitfalls of chimeric antigen receptors. (2009) (455)
- Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication. (2010) (443)
- Conserved vertebrate mir-451 provides a platform for Dicer-independent, Ago2-mediated microRNA biogenesis (2010) (426)
- Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts (2007) (414)
- Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity (2014) (399)
- Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. (2010) (387)
- The pharmacology of second-generation chimeric antigen receptors (2015) (383)
- Safe harbours for the integration of new DNA in the human genome (2011) (382)
- Imaging transgene expression with radionuclide imaging technologies. (2000) (371)
- Generation of tumor-targeted human T lymphocytes from induced pluripotent stem cells for cancer therapy (2013) (336)
- Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. (2003) (335)
- Senolytic CAR T cells reverse senescence-associated pathologies (2020) (333)
- Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. (1994) (330)
- Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. (2016) (305)
- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape (2019) (303)
- Prevention of Type I Diabetes in NOD Mice by Adjuvant Immunotherapy (1990) (302)
- Genomic safe harbors permit high β-globin transgene expression in thalassemia induced pluripotent stem cells (2011) (301)
- Stoichiometric and temporal requirements of Oct4, Sox2, Klf4, and c-Myc expression for efficient human iPSC induction and differentiation (2009) (280)
- T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection (2007) (278)
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency (2018) (276)
- A Herceptin-Based Chimeric Antigen Receptor with Modified Signaling Domains Leads to Enhanced Survival of Transduced T Lymphocytes and Antitumor Activity1 (2009) (275)
- Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. (2000) (272)
- Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy (2009) (263)
- Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. (2006) (259)
- Antigen-dependent CD28 Signaling Selectively Enhances Survival and Proliferation in Genetically Modified Activated Human Primary T Lymphocytes (1998) (249)
- The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells (2019) (248)
- Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. (1999) (228)
- A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. (2003) (225)
- Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes (2003) (217)
- Imaging transcriptional regulation of p53-dependent genes with positron emission tomography in vivo (2001) (215)
- Occurrence of leukaemia following gene therapy of X-linked SCID (2003) (214)
- The cHS4 Insulator Increases the Probability of Retroviral Expression at Random Chromosomal Integration Sites (2000) (201)
- Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML. (2017) (197)
- Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. (2016) (195)
- Generation of a high-titer retroviral vector capable of expressing high levels of the human beta-globin gene. (1995) (194)
- Complete Freund's adjuvant-induced T cells prevent the development and adoptive transfer of diabetes in nonobese diabetic mice. (1993) (191)
- Migration and differentiation of neural precursors derived from human embryonic stem cells in the rat brain (2005) (187)
- CAR therapy: the CD19 paradigm. (2015) (187)
- The journey from discoveries in fundamental immunology to cancer immunotherapy. (2015) (183)
- The ABCs of artificial antigen presentation (2004) (181)
- Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells (2000) (179)
- IL-7 and IL-21 are superior to IL-2 and IL-15 in promoting human T cell-mediated rejection of systemic lymphoma in immunodeficient mice. (2010) (178)
- Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. (1997) (175)
- Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor β2 (IL-12Rβ2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. (2013) (175)
- Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity (2017) (164)
- Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. (2001) (162)
- Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML (2018) (161)
- Intercellular transfer of P-glycoprotein mediates acquired multidrug resistance in tumor cells. (2005) (155)
- Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy (2021) (154)
- Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells (2018) (154)
- Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. (2001) (154)
- Occurrence of leukaemia following gene therapy of X-linked SCID (2003) (152)
- Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients (2012) (149)
- American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. (2003) (148)
- CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia (2013) (140)
- Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene (2002) (140)
- Mechanogenetics for the remote and noninvasive control of cancer immunotherapy (2018) (134)
- New cell sources for T cell engineering and adoptive immunotherapy. (2015) (130)
- miR-371-3 expression predicts neural differentiation propensity in human pluripotent stem cells. (2011) (130)
- CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. (2004) (130)
- Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase (2009) (123)
- Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors (2008) (121)
- Genetic treatment of severe hemoglobinopathies: the combat against transgene variegation and transgene silencing. (1998) (121)
- Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression. (1999) (120)
- CARs on track in the clinic. (2011) (116)
- Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape. (2018) (115)
- Targeted elimination of prostate cancer by genetically directed human T lymphocytes. (2005) (114)
- Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma (2013) (114)
- A genetic strategy to treat sickle cell anemia by coregulating globin transgene expression and RNA interference (2006) (110)
- Toxicity and Response following CD19-specific CAR T cells in pediatric/young adult relapsed/refractory B-ALL. (2019) (109)
- A general approach to the non-invasive imaging of transgenes using cis-linked herpes simplex virus thymidine kinase. (1999) (105)
- A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD-1 agent pembrolizumab. (2021) (102)
- A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? (2001) (96)
- Involvement of interleukin-3 in delayed-type hypersensitivity. (1998) (94)
- Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. (1997) (90)
- Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor–engineered T Cells (2019) (89)
- Mass cultured human fibroblasts overexpressing hTERT encounter a growth crisis following an extended period of proliferation. (2000) (88)
- Human ESC-derived hemogenic endothelial cells undergo distinct waves of endothelial to hematopoietic transition. (2013) (85)
- The genetic engineering of hematopoietic stem cells: the rise of lentiviral vectors, the conundrum of the ltr, and the promise of lineage-restricted vectors. (2007) (85)
- Cell and Gene Therapy for the Beta-Thalassemias: Advances and Prospects. (2016) (84)
- Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. (2002) (84)
- Negative-Feedback Regulation of CD28 Costimulation by a Novel Mitogen-Activated Protein Kinase Phosphatase, MKP61 2 (2001) (84)
- CD19 CAR T Cells (2017) (83)
- Prevention of diabetes in the BB rat by early immunotherapy using Freund's adjuvant. (1990) (82)
- Monitoring the Efficacy of Adoptively Transferred Prostate Cancer–Targeted Human T Lymphocytes with PET and Bioluminescence Imaging (2008) (82)
- Insertional oncogenesis in gene therapy: how much of a risk? (2004) (82)
- In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. (2011) (80)
- Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation. (2019) (80)
- Stem cell–derived erythroid cells mediate long-term systemic protein delivery (2006) (80)
- A Genetic Strategy for Single and Combinatorial Analysis of miRNA Function in Mammalian Hematopoietic Stem Cells (2009) (79)
- Retrovirally Transduced Mouse Dendritic Cells Require CD4+ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells1 (2000) (79)
- Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. (2017) (78)
- Genome editing technologies: defining a path to clinic. (2015) (77)
- Multiple stages of malignant transformation of human endothelial cells modelled by co-expression of telomerase reverse transcriptase, SV40 T antigen and oncogenic N-ras (2002) (75)
- Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients (2011) (74)
- Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)–an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT) (2019) (74)
- Generation of transgene-free human induced pluripotent stem cells with an excisable single polycistronic vector (2011) (73)
- Hematopoietic stem cell engineering at a crossroads. (2012) (73)
- Biology and clinical application of CAR T cells for B cell malignancies (2016) (72)
- Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele. (2003) (70)
- Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent. (2019) (70)
- Safe mobilization of CD34+ cells in adults with β-thalassemia and validation of effective globin gene transfer for clinical investigation. (2014) (69)
- Prostate‐specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer (2009) (69)
- In vivo imaging and quantitation of adoptively transferred human antigen-specific T cells transduced to express a human norepinephrine transporter gene. (2007) (68)
- An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity (2017) (68)
- Rapid selection of antigen-specific T lymphocytes by retroviral transduction. (2000) (67)
- A method to sequence and quantify DNA integration for monitoring outcome in gene therapy (2011) (67)
- The potential of stem cells as an in vitro source of red blood cells for transfusion. (2012) (67)
- Active site-directed double mutants of dihydrofolate reductase. (1996) (66)
- Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma (2012) (66)
- Chimeric antigen receptors: driving immunology towards synthetic biology. (2016) (65)
- The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes (1997) (62)
- Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras. (2008) (61)
- T-cell therapy at the threshold (2012) (61)
- Prostate-specific Membrane Antigen (PSMA)-specific Monoclonal Antibodies in the Treatment of Prostate and Other Cancers (2004) (61)
- Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells. (2005) (59)
- Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy. (2018) (59)
- Posttransplant chimeric antigen receptor therapy. (2018) (59)
- Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL. (2019) (58)
- Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination (2005) (56)
- Chimeric antigen receptor (CAR+) modified T cells targeting prostate-specific membrane antigen (PSMA) in patients (pts) with castrate metastatic prostate cancer (CMPC). (2013) (54)
- A New Pyrimidine-Specific Reporter Gene: A Mutated Human Deoxycytidine Kinase Suitable for PET During Treatment with Acycloguanosine-Based Cytotoxic Drugs (2010) (53)
- Equal transcription of wild-type and mutant p53 using bicistronic vectors results in the wild-type phenotype. (1994) (53)
- Large-scale Clinical-grade Retroviral Vector Production in a Fixed-Bed Bioreactor (2015) (52)
- Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy (2022) (52)
- Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. (2006) (52)
- Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition (2015) (52)
- Generation of dual resistance to 4-hydroperoxycyclophosphamide and methotrexate by retroviral transfer of the human aldehyde dehydrogenase class 1 gene and a mutated dihydrofolate reductase gene. (2001) (51)
- Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia (2006) (50)
- Implications of Minimal Residual Disease Negative Complete Remission (MRD-CR) and Allogeneic Stem Cell Transplant on Safety and Clinical Outcome of CD19-Targeted 19-28z CAR Modified T Cells in Adult Patients with Relapsed, Refractory B-Cell ALL (2015) (50)
- CD19 CAR T Cells Following Autologous Transplantation in Poor Risk Relapsed and Refractory B cell non-Hodgkin Lymphoma. (2019) (49)
- Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in beta-thalassemic mice. (2007) (49)
- Ligand Binding to Inhibitory Killer Cell Ig-Like Receptors Induce Colocalization with Src Homology Domain 2-Containing Protein Tyrosine Phosphatase 1 and Interruption of Ongoing Activation Signals1 (2004) (49)
- CD19 CAR Therapy for Acute Lymphoblastic Leukemia. (2015) (48)
- T-cell engineering for cancer immunotherapy. (2009) (47)
- T-cell immunotherapy: looking forward. (2014) (47)
- ASGCT and JSGT Joint Position Statement on Human Genomic Editing. (2015) (46)
- Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy. (2015) (46)
- Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma (2011) (45)
- Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. (2018) (45)
- How do CARs work? (2012) (41)
- Erythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B mice. (2008) (41)
- Retroviral transduction of murine primary T lymphocytes. (2009) (40)
- A Phase I First-in-Human Clinical Trial of CD19-Targeted 19-28z/4-1BBL "Armored" CAR T Cells in Patients with Relapsed or Refractory NHL and CLL Including Richter's Transformation (2018) (40)
- Limited proliferation and telomere dysfunction following telomerase inhibition in immortal murine fibroblasts. (2002) (40)
- Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in β‐thalassemia (2010) (40)
- Production of clinical-grade plasmid DNA for human Phase I clinical trials and large animal clinical studies. (2007) (40)
- Current status of globin gene therapy for the treatment of β‐thalassaemia (2008) (40)
- Activation conditions determine susceptibility of murine primary T‐lymphocytes to retroviral infection (1999) (39)
- Concurrent visualization of trafficking, expansion, and activation of T lymphocytes and T-cell precursors in vivo. (2010) (39)
- Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results (2018) (38)
- [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity (2006) (38)
- Toward gene therapy for disorders of globin synthesis. (2001) (37)
- Phase I trial of 19-28z chimeric antigen receptor modified T cells (19-28z CAR-T) post-high dose therapy and autologous stem cell transplant (HDT-ASCT) for relapsed and refractory (rel/ref) aggressive B-cell non-Hodgkin lymphoma (B-NHL). (2015) (37)
- Methods for the construction of retroviral vectors and the generation of high-titer producers. (1997) (37)
- Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. (2007) (36)
- Efficacy and safety of CD19-targeted 19-28z CAR modified T cells in adult patients with relapsed or refractory B-ALL. (2015) (36)
- Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells (2000) (35)
- Progress Toward the Genetic Treatment of the β‐Thalassemias (2005) (34)
- High-Throughput Sequencing Reveals Principles of Adeno-Associated Virus Serotype 2 Integration (2013) (34)
- Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells (2014) (33)
- HLA-independent T cell receptors for targeting tumors with low antigen density (2022) (32)
- Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes (2018) (31)
- Early experience using salvage radiotherapy for relapsed/refractory non‐Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy (2020) (31)
- Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in Cell Factories (2006) (31)
- Abstract CT036: A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy (2019) (31)
- Development of a new reporter gene system--dsRed/xanthine phosphoribosyltransferase-xanthine for molecular imaging of processes behind the intact blood-brain barrier. (2003) (30)
- Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL. (2016) (30)
- Fetal gene therapy of α-thalassemia in a mouse model (2007) (30)
- Chimeric Antigen Receptors: A Paradigm Shift in Immunotherapy (2017) (29)
- Stable in vivo expression of glucose-6-phosphate dehydrogenase (G6PD) and rescue of G6PD deficiency in stem cells by gene transfer. (2000) (28)
- Interventions and Outcomes of Adult Patients with B-ALL Progressing After CD19 Chimeric Antigen Receptor T Cell Therapy. (2021) (28)
- Busulfan pharmacokinetics, toxicity, and low-dose conditioning for autologous transplantation of genetically modified hematopoietic stem cells in the rhesus macaque model. (2006) (28)
- Negative-Feedback Regulation of CD28 Costimulation by a Novel Mitogen-Activated Protein Kinase Phosphatase, MKP6 (2000) (27)
- A Panel of Artificial APCs Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Dominant and Subdominant Viral Epitopes for Adoptive Therapy1 (2009) (27)
- Neoantigen quality predicts immunoediting in survivors of pancreatic cancer (2022) (27)
- Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1 (2017) (27)
- Stem cell engineering for the treatment of severe hemoglobinopathies. (2008) (26)
- Baseline and early post-treatment clinical and laboratory factors associated with severe neurotoxicity following 19-28z CAR T cells in adult patients with relapsed B-ALL. (2017) (26)
- CAR T cells: Building on the CD19 paradigm (2021) (25)
- Benefits of utilizing gene-modified iPSCs for clinical applications. (2010) (25)
- Retroviral-mediated gene transfer in primary murine and human T-lymphocytes (2000) (24)
- Gene therapy through autologous transplantation of gene-modified hematopoietic stem cells. (2013) (24)
- Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity. (2013) (24)
- Therapeutic globin gene delivery using lentiviral vectors. (2002) (24)
- Animal models and molecular imaging tools to investigate lymph node metastases (2011) (24)
- Adenoviral Transduction of Human Acid Sphingomyelinase into Neo-Angiogenic Endothelium Radiosensitizes Tumor Cure (2013) (24)
- Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. (2013) (23)
- Genome Editing Technologies: Defining a Path to Clinic: Genomic Editing: Establishing Preclinical Toxicology Standards, Bethesda, Maryland 10 June 2014. (2015) (22)
- GENETIC TREATMENT OF THE HAEMOGLOINOPATHIES: RECOMBINATIONS AND NEW COMBINATIONS (1997) (22)
- Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy. (2016) (22)
- Development of citrullinated-vimentin-specific CAR for targeting Tregs to treat autoimmune rheumatoid arthritis (2016) (22)
- CD19-Targeted 19-28z CAR Modified Autologous T Cells Induce High Rates of Complete Remission and Durable Responses in Adult Patients with Relapsed, Refractory B-Cell ALL (2014) (21)
- Soluble and membrane‐bound interleukin (IL)‐15 Rα/IL‐15 complexes mediate proliferation of high‐avidity central memory CD8+ T cells for adoptive immunotherapy of cancer and infections (2016) (20)
- Cutting Edge: CD28 Controls Dominant Regulatory T Cell Activity during Active Immunization1 (2006) (20)
- Screening Clinical Cell Products for Replication Competent Retrovirus: The National Gene Vector Biorepository Experience (2018) (20)
- Escape Mutations, Ganciclovir Resistance, and Teratoma Formation in Human iPSCs Expressing an HSVtk Suicide Gene (2016) (19)
- Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence (2021) (19)
- MSKCC EARLY EXPERIENCE USING RADIOTHERAPY AS A BRIDGING STRATEGY FOR RELAPSED DIFFUSE LARGE B CELL LYMPHOMA BEFORE CD19 CAR T THERAPY (2019) (18)
- Langerhans Cells Derived from Genetically Modified Human CD34+ Hemopoietic Progenitors Are More Potent Than Peptide-Pulsed Langerhans Cells for Inducing Antigen-Specific CD8+ Cytolytic T Lymphocyte Responses1 (2005) (18)
- Gene Therapy and Genome Editing. (2018) (18)
- Durable long-term survival of adult patients with relapsed B-ALL after CD19 CAR (19-28z) T-cell therapy. (2017) (18)
- Globin gene transfer for the treatment of severe hemoglobinopathies: a paradigm for stem cell‐based gene therapy (2002) (18)
- Globin gene transfer for treatment of the β-thalassemias and sickle cell disease (2004) (17)
- Adenovirus facilitated infection of human cells with ecotropic retrovirus (1998) (17)
- CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models. (2013) (17)
- Fetal gene therapy of alpha-thalassemia in a mouse model. (2007) (16)
- Novel strategies for cancer therapy: the potential of genetically modified T lymphocytes. (2004) (16)
- Sturm und drang over suicidal lymphocytes. (2002) (16)
- An In Vivo Platform for Tumor Biomarker Assessment (2011) (16)
- Biomarkers associated with neurotoxicity in adult patients with relapsed or refractory B-ALL (R/R B-ALL) treated with CD19 CAR T cells. (2017) (16)
- Progress toward the genetic treatment of the beta-thalassemias. (2005) (16)
- Safety and efficacy of plerixafor dose escalation for the mobilization of CD34+ hematopoietic progenitor cells in patients with sickle cell disease: interim results (2018) (15)
- Derivation of genetically modified human pluripotent stem cells with integrated transgenes at unique mapped genomic sites (2011) (15)
- Globin gene transfer for treatment of the beta-thalassemias and sickle cell disease. (2004) (14)
- Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult acute lymphoblastic leukemia (2021) (14)
- A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma (2021) (14)
- T cell activation upon exposure to patient-derived tumor tissue: a functional assay to select patients for adoptive T cell therapy. (2010) (14)
- Recovery and Biodistribution of Ex Vivo Expanded Human Erythroblasts Injected into NOD/SCID/IL2Rγnull mice (2011) (14)
- Reprint of: Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. (2018) (14)
- T-Cell Immunotherapy: Looking Forward: T Cell Immunotherapy: Optimizing Trial Design Bethesda, Maryland 10-11 September 2013. (2014) (14)
- Clinical and Biologic Correlates of Neurotoxicity Associated with CAR T Cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia (B-ALL) (2018) (14)
- Eliminating cells gone astray. (2011) (14)
- Impact of the Conditioning Chemotherapy On Outcomes in Adoptive T Cell Therapy: Results From a Phase I Clinical Trial of Autologous CD19-Targeted T Cells for Patients with Relapsed CLL (2012) (13)
- Corrigendum: Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling (2009) (13)
- The quest for spatio-temporal control of CAR T cells (2015) (13)
- Impact of bridging chemotherapy on clinical outcome of CD19 CAR T therapy in adult ALL. (2019) (13)
- Towards the genetic treatment of β-thalassemia: new disease models, new vectors, new cells (2008) (13)
- Implications of Concurrent Ibrutinib Therapy on CAR T-Cell Manufacturing and Phenotype and on Clinical Outcomes Following CD19-Targeted CAR T-Cell Administration in Adults with Relapsed/Refractory CLL (2016) (13)
- Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells (2022) (12)
- FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial (2019) (12)
- Multi-Center Clinical Trial of CAR T Cells in Pediatric/Young Adult Patients with Relapsed B-Cell ALL (2015) (12)
- Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL. (2014) (12)
- Supplying clotting factors from hematopoietic stem cell-derived erythroid and megakaryocytic lineage cells. (2009) (12)
- Safe and Effective Re-Induction Of Complete Remissions In Adults With Relapsed B-ALL Using 19-28z CAR CD19-Targeted T Cell Therapy (2013) (12)
- A promising genetic approach to the treatment of beta-thalassemia. (2001) (12)
- Combinatorial Antigen Targeting: Ideal T-Cell Sensing and Anti-Tumor Response. (2016) (11)
- Transient in vivo beta-globin production after lentiviral gene transfer to hematopoietic stem cells in the nonhuman primate. (2009) (11)
- PHASE I CLINICAL TRIAL OF CD19‐TARGETED 19‐28Z/4‐1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION (2019) (11)
- CARs on Track in the Clinic: Workshop of the Blood and Marrow Transplant Clinical Trials Network Subcommittee on Cell and Gene Therapy Washington DC, 18 May 2010. (2011) (11)
- Host natural suppressor activity regulates hemopoietic engraftment kinetics in antibody-conditioned recipient mice. (1990) (11)
- CD19-directed chimeric antigen receptor T cell therapy in Waldenström macroglobulinemia: a preclinical model and initial clinical experience (2022) (11)
- Highly Divergent Integration Profile of Adeno-Associated Virus Serotype 5 Revealed by High-Throughput Sequencing (2013) (11)
- Durable Remission Following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies (2020) (11)
- Retroviral transfer of herpes simplex virus-thymidine kinase and beta-galactosidase genes into U937 cells with bicistronic vector. (1997) (11)
- Cas9-Cleavage Sequences in Size-Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T Cells. (2021) (10)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial (2022) (9)
- Reconstructing blood from induced pluripotent stem cells (2010) (9)
- Functional assessment of the engraftment potential of gammaretrovirus-modified CD34+ cells, using a short serum-free transduction protocol. (2006) (9)
- A cell engineering strategy to enhance the safety of stem cell therapies. (2014) (9)
- Genetic strategies for the treatment of sickle cell anaemia (2011) (9)
- Methods for retrovirus-mediated gene transfer into primary T-lymphocytes. (1997) (9)
- The role of natural suppressor and natural killer activities in resistance to hemopoietic transplantation in unirradiated hosts. (1989) (9)
- Development of a New Reporter Gene System-dsRed/Xanthine Phosphoribosyltransferase-Xanthine for Molecular Imaging of Processes Behind the Intact Blood-Brain Barrier (2003) (9)
- PLZF confers effector functions to donor T cells that preserve graft-versus-tumor effects while attenuating GVHD. (2013) (8)
- Globin gene transfer: a paradigm for transgene regulation and vector safety (2003) (8)
- Langerhans-Type Dendritic Cells Genetically Modified to Express Full-Length Antigen Optimally Stimulate CTLs in a CD4-Dependent Manner1 (2006) (8)
- Targeting castration resistant prostate cancer (CRPC) with autologous PSMA-directed CAR+ T cells. (2012) (8)
- Delayed activation of quiescent donor hematopoietic stem cells in the host marrow cavity by anti-host monoclonal antibody (1989) (8)
- Glucose 6-phosphate dehydrogenase expression is less prone to variegation when driven by its own promoter. (2001) (8)
- Artificial antigen presenting cells that express prevalent HLA alleles: A step towards the broad application of antigen-specific adoptive cell therapies. (2009) (7)
- CD19 Targeted Allogeneic EBV-Specific T Cells for the Treatment of Relapsed ALL in Pediatric Patients Post HSCT (2012) (7)
- Abstract CT102: Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia (2014) (7)
- Abstract LB-108: Generation of off-the-shelf TCR-less CAR-targeted cytotoxic T cells from renewable pluripotent cells for cancer immunotherapy (2018) (7)
- Imaging Transgene Expression for Gene Therapy (1999) (7)
- A novel murine model of Cooley’s anemia and its rescue by lentiviral mediated human ß-globin gene transfer (2002) (7)
- Why commonplace encounters turn to fatal attraction (1998) (7)
- CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade (2018) (7)
- Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC) DOD Grant Log# PC081632, PI: Slovin, SF (2008) (7)
- Pluripotent Cell-Derived Off-the-Shelf TCR-Less CAR-Targeted Cytotoxic T Cell Therapeutic for the Allogeneic Treatment of B Cell Malignancies (2018) (6)
- Gene Therapy for Homozygous β -thalassemia. Is it a Reality? (2009) (6)
- Updated results: phase I trial of autologous CD19-targeted CAR T cells in patients with residual CLL following initial purine analog-based therapy. (2016) (6)
- Adeno-associated virus type 2 preferentially integrates single genome copies with defined breakpoints (2014) (6)
- Recovery and Biodistribution of Ex-Vivo Expanded Human Erythroblasts Injected Into NOD/SCID/IL2Rγnull Mice (2010) (6)
- Ectopic activation of the miR-200c–EpCAM axis enhances antitumor T cell responses in models of adoptive cell therapy (2021) (6)
- Title: Locus control region elements HS1 and HS4 enhance the therapeutic efficacy of globin gene transfer in β-thalassemic mice Running title: New globin lentiviral vectors for β-thalassemia. (2007) (6)
- Tales of Antigen Evasion from CAR Therapy (2016) (6)
- Function and evolution of the prototypic CD28ζ and 4-1BBζ chimeric antigen receptors (2020) (6)
- gene-globin β human-thalassemia intermedia by transfer of the β Successful treatment of murine (2002) (6)
- Concurrent therapy of chronic lymphocytic leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia utilizing CD19-targeted CAR T-cells (2018) (6)
- Abstract LB-378: Regional delivery of clinical-grade mesothelin-targeted CAR T cells with cell-intrinsic PD-1 checkpoint blockade: Translation to a phase I trial (2020) (6)
- The Polycomb Group Protein L3MBTL1 Represses a SMAD5-Mediated Hematopoietic Transcriptional Program in Human Pluripotent Stem Cells (2015) (6)
- Frequency of Missense Mutations in the Coding Region of a Eukaryotic Gene Transferred by Retroviral Vectors (2002) (6)
- Proceedings of the 2016 China Cancer Immunotherapy Workshop (2016) (6)
- Gene therapy--the challenge for the future. (1996) (6)
- 274. One-Step Generation of Universal CAR T Cells (2016) (5)
- Adoptive-transfer therapy of tumors with the tumor-specific primary cytotoxic T cells induced in vitro with the B7.1-transduced MCA205 cell line (1999) (5)
- First US Phase I Clinical Trial Of Globin Gene Transfer For The Treatment Of Beta-Thalassemia Major (2013) (5)
- A phase I trial for the treatment of purine analog-refractory chronic lymphocytic leukemia using autologous T cells genetically targeted to the B cell specific antigen CD19 (2008) (5)
- Phase I Trial Of Autologous CD19-Targeted CAR-Modified T Cells As Consolidation After Purine Analog-Based First-Line Therapy In Patients With Previously Untreated CLL (2013) (5)
- Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated with autologous, CD19-targeted T cells. (2011) (5)
- Estimation of empirical null using a mixture of normals and its use in local false discovery rate (2011) (5)
- Radiation Sensitizes Tumor Cells to CAR T Cell Immunotherapy (2016) (5)
- Basic principles of gene transfer in hematopoietic stem cells. (1999) (5)
- Scalable Expansion of Potent Genetically Modified Human Langerhans Cells in a Closed System for Clinical Applications (2007) (5)
- A phase I trial of CD19-targeted EGFRt/19-28z/4-1BBL armored chimeric antigen receptor (CAR) modified T cells in patients with relapsed or refractory chronic lymphocytic leukemia. (2017) (5)
- Tetracycline-mediated suppression of gene expression with a new dicistronic retroviral vector. (1997) (4)
- The need for genetically engineering therapeutic pluripotent stem cells. (2010) (4)
- Globin gene transfer as a potential treatment for the β‐thalassaemias and sickle cell disease (2004) (4)
- Neurotoxicity Associated with CD19-specific Chimeric Antigen Receptor T cell Therapy for Adult Acute Lymphoblastic Leukemia (B-ALL) (S23.008) (2018) (4)
- Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency (2019) (4)
- From the guest editor: The rise of CAR therapy: the CD19 paradigm, and beyond. Introduction. (2014) (4)
- 459. Evaluation of Miltenyi ExpAct and TransAct CD3/28 Beads for CAR-T Cell Manufacturing (2016) (4)
- The Advent of Lentiviral Vectors: Prospects for Cancer Therapy (2002) (4)
- Somatic cell engineering and the immunotherapy of leukemias and lymphomas. (2004) (4)
- TET2 guards against unchecked BATF3-induced CAR T cell expansion (2023) (3)
- Efficient retroviral infection of human cells utilising an adenoviral vector expressing the ecotropic receptor. (1998) (3)
- A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory B-Cell Malignancies (2020) (3)
- Abstract 3245: FT819 path to IND: First-of-kind off-the-shelf CAR19 T-cell for B cell malignancies (2020) (3)
- Abstract CT078: Impact of disease burden and transplant on long-term survival after CD19 CAR therapy in adults with relapsed B-cell acute lymphoblastic leukemia (2017) (3)
- Severe delayed hemolytic transfusion reaction due to anti-Fy3 in a patient with sickle cell disease undergoing red cell exchange prior to hematopoietic progenitor cell collection for gene therapy (2020) (3)
- Quantitative analysis of clinically relevant mutations occurring in lymphoid cells harboring γ-retrovirus-encoded hsvtk suicide genes (2008) (3)
- Fulminant experimental autoimmune encephalo‐myelitis induced by retrovirally mediated TCR gene transfer (2005) (3)
- A PHASE I TRIAL OF 19‐28Z CAR‐T CELLS POST‐HIGH DOSE THERAPY AND AUTOLOGOUS TRANSPLANTATION (HDT‐ASCT) FOR RELAPSED AND REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) (2017) (3)
- Chimeric Antigen Receptor (CAR) T Cells Targeting the CD19 Antigen for the Treatment of Pediatric Relapsed B Cell ALL (2014) (3)
- Tolerance induction by allogeneic hematopoietic stem cells. (2011) (3)
- The Importance of the Human β-Globin Locus Control Region HS1 and HS4 Elements for Therapeutic β-Globin Gene Expression in β-Thalassemic Mice. (2007) (3)
- Targeted ‘Off-the-Shelf’ Tumor Immunotherapy Using Allogeneic T-Cell Precursors. (2007) (3)
- Delayed activation of quiescent donor hematopoietic stem cells in the host marrow cavity by anti-host monoclonal antibody. (1989) (3)
- Comparative Blood Group Profiling of Human Erythroid Cells (EBs) Generated from Adult Blood (AB), Cord Blood (CB), Human Embryonic Stem Cells (hESC) and Induced Pluripotent Stem Cells (iPS) (2011) (3)
- Abstract IA07: Chimeric antigen receptor T cells for cancer immunotherapy (2016) (3)
- CD19-Targeted Donor T Cells Exert Potent Graft Versus Lymphoma Activity and Attenuated Gvhd (2012) (3)
- S1634 A PHASE I FIRST-IN-HUMAN CLINICAL TRIAL OF CD19-TARGETED 19–28Z/4–1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION (2019) (3)
- T Cell Immunotherapy: Optimizing Trial Design (2014) (3)
- 268. CD19-Targeted Normal and CLL Patient T Cells Expanded with Beads Can Eradicate Systemic Tumors In Vivo (2006) (2)
- A Panel of Artificial Antigen-Presenting Cells (AAPC) Expressing Prevalent HLA Alleles Permits Generation of Cytotoxic T Cells Specific for Both Subdominant and Dominant Viral Epitopes for Adoptive Therapy. (2007) (2)
- A New Induction to the Gene and Cell Therapy Hall Of Fame: Genome Editing. (2016) (2)
- Conditioning Prior to CAR T Cells Predicts Response and Survival in Pediatric/Young Adult Relapse/Refractory (R/R) B-ALL (2019) (2)
- From T-cell Engineering to CAR therapy: Progress and Prospects (2015) (2)
- From Adoptive Immunity to CAR Therapy: An Evolutionary Perspective (2016) (2)
- Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies. (2020) (2)
- 269. Integrated CD28 and 4-1BB Signals Strongly Potentiate CD8+ T Cell Mediated radication of Metastatic Prostate Cancer (2006) (2)
- The Meaning of Translation (2006) (2)
- "IF-Better" Gating: Combinatorial Targeting and Synergistic Signaling for Enhanced CAR T Cell Efficacy (2021) (2)
- Enhanced In Vivo activation of Adoptively Transferred Genetically Targeted T Cells Following Cyclophosphamide Chemotherapy: Initial Results From a Phase I Clinical Trial Treating CLL Patients with Autologous CD19-Targeted T Cells. (2009) (2)
- The role of natural suppression in mediating resistance to antibody-facilitated bone marrow engraftment. (1989) (2)
- IL-15 Enhances in-vitro Expansion And Functional Activity Of Antigen-Specific Effector Memory T Cells (TEM) While Co-Expression Of IL-15 And IL-15 Rα On Antigen Presenting Cells Also Promotes Enrichment And Preferential Expansion Of Central Memory T-Cells (TCM) (2010) (2)
- Potent Synergy between Combination of Chimeric Antigen Receptor (CAR) Therapy Targeting CD19 in Conjunction with Dendritic Cell (DC)/Tumor Fusion Vaccine in Hematological Malignancies (2019) (2)
- Workshop of the Blood and Marrow Transplant Clinical Trials Network Subcommittee on Cell and Gene Therapy (2011) (1)
- Process and procedural adjustments to improve CD34+ collection efficiency of hematopoietic progenitor cell collections in sickle cell disease (2021) (1)
- Generation of Clonal Antigen Specific CD8αβ+ Cytotoxic T Lymphocytes from Renewable Pluripotent Stem Cells for Off-the-Shelf T Cell Therapeutics (2017) (1)
- A "friendly merger" in the war on cancer. (2000) (1)
- Murine Donor 1928z CAR T Cells Exert Potent Graft-Versus-Lymphoma Activity without Graft-Versus-Host-Disease (2016) (1)
- Mesothelin-targeted T Cells Gene-Engineered with 4-1BB Costimulation Overcome Tumor-Mediated Immunoinhibition and Eradicate Established Solid Tumors (2014) (1)
- Generation of T Cells of Desired HLA Restriction Specific for Epitopes of a Self-Antigen, WT1, for the Adoptive Immunotherapy of WT1 Positive Malignancies Using A Panel of Artificial Antigen Presenting Cells Expressing Prevalent HLA Alleles. (2009) (1)
- Loss of TET2 Uncouples Proliferative and Effector Functions in CAR T Cells (2020) (1)
- A Panel of Artificial Antigen Presenting Cells (AAPC) Permits Immediate Sensitization and Rapid Generation of Virus-Specific T-Cells of Desired HLA Restriction for Adoptive Immunotherapy. (2006) (1)
- Virus Specific T-Lymphocytes Genetically Modified to Target the CD19 Antigen Eradicates Systemic Lymphoma In Mice (2010) (1)
- IL-15 Augments in-Vitro Expansion and Functional Activity of Antigen-Specific Effector Memory T-Cells (TEM) While Co-Expression of IL-15 and IL-15 Rα on Antigen Presenting Cells Also Promotes Expansion of Central Memory T-Cells (TCM) (2008) (1)
- Establishing cGMP manufacturing of CRISPR/Cas9-edited human CAR T cells (2020) (1)
- 207. Optimal Activation of Both CD28 and 4-1BB in CAR-Targeted T Cells Results in Enhanced Tumor Eradication (2015) (1)
- Generation of a high-titer retroviral vector capable of expressing high levels of the human ( 8-globin gene ( hemoglobinopathies / gene therapy / locus control region ) (2005) (1)
- NOTCH and CAR Signaling Control T Cell Lineage Commitment from Pluripotent Stem Cells (2020) (1)
- Molecular Remission and B Cell Aplasia Induced in a First Cohort of Adults with Relapsed B-ALL Treated with 19–28z CAR-Targeted T Cells (2012) (1)
- The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. (2022) (1)
- Novel extragenic genomic safe harbors for precise therapeutic T cell engineering. (2023) (1)
- 475. Phase I Clinical Trial of Autologous CD19-Targeted 19-28z CAR T Cells in Adult Patients With Relapsed or Refractory B-ALL (2015) (1)
- Engineered Antigen- Presenting Cells Expressing Human HLA Class-II DR Alleles Support Efficient Enrichment and Expansion of Antigen Specific Th1 CD4[+] T-Cells Which Are Functionally Augmented by IL-15Rα/IL-15 Complexes (2012) (1)
- The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies (2021) (1)
- CD19 CAR antigen engagement mechanisms and affinity tuning (2023) (1)
- 72. Position and Copy Number Dependence of the Central Polypurine Tract (cPPT) Function in Simple and Complex Lentiviral Vectors (2004) (1)
- Abstract 2567: Novel therapeutic interventions to alleviate CAR T cell-induced cytokine release syndrome (2018) (1)
- Abstract LB153: Emergence of a hyper-proliferative phenotype inTET2edited human CAR T cells (2021) (1)
- Evidence for continued dose escalation of plerixafor for hematopoietic progenitor cell collections in sickle cell disease. (2021) (1)
- A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (2022) (1)
- Abstract B27: A preclinical mouse model of orthotopic pleural cancer that facilitates noninvasive quantitative monitoring of tumor progression and therapy response (2009) (1)
- Human Norepinephrine Transporter Gene Human Antigen-Specific T Cells Transduced to Express a Imaging and Quantitation of Adoptively Transferred In vivo (2007) (1)
- Faculty Opinions recommendation of Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. (2010) (1)
- Immuno gene therapy comes into its own (1997) (1)
- Genetic treatment of severe hemoglobinopathies (2000) (1)
- Mechanisms that determine host resistance to bone marrow stem cell engraftment in unirradiated hosts (1988) (1)
- Artificial Antigen-Presenting Cells Permit Selective In Vitro Generation of CMV-Specific T-Cells of Desired HLA Allelic Restriction for Adoptive Immunotherapy in Recipients of HLA Disparate Allografts. (2005) (1)
- 4-1BBL costimulation enables CD4 T cells expressing a CD28/zeta chimeric antigen receptor to eliminate aggressive leukemia. (P4338) (2013) (1)
- Globin vector regulatory elements are active in early hematopoietic progenitor cells. (2022) (1)
- LiPS-A3S, a human genomic site for robust expression of inserted transgenes (2016) (1)
- Probing the AML Surfaceome for Chimeric Antigen Receptor (CAR) Targets (2016) (1)
- Over-Expression of TRAIL on Donor T Cells Enhances GVT and Suppresses Gvhd Via Elimination of Alloreactive T Cells and Host APC (2011) (1)
- Adeno-associated virus type 2 preferentially integrates single genome copies with defined breakpoints (2014) (1)
- Lentivirus-transduced human monocyte-derived dendritic cells (2000) (1)
- Generation of CMV-Specific T-Lymphocytes for Adoptive Immunotherapy: A Comparison of Artificial Antigen-Presenting Cells and Autologous Dendritic Cells Pulsed with CMV-pp65 Protein-Spanning Pentadecapeptide Pools. (2005) (0)
- Graded potency of chimeric antigen receptor (CAR)-engineered T cells for cancer immunotherapy. (2014) (0)
- Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma. (2023) (0)
- Cancer Vaccines: Gene Therapy and Dendritic Cell-Based Vaccines (2002) (0)
- 608: Neutral Endopeptidase Targeted to Prostate Cancer Cells Via Fusion with an Anti-Prostate Specific Membrane Antigen Monoclonal Antffiody (2004) (0)
- CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape (2019) (0)
- 1055. High Levels of Human Factor IX Expression in Hemophilia B Mice after Adult Stem Cell-Based Gene Therapy Combined with Non-Myeloablative Conditioning (2006) (0)
- Mesothelin Expression Promotes An Aggressive Phenotype Of Non-Small Cell Lung Cancer (NSCLC) (2011) (0)
- 707. Transduction and Expansion of T Lymphocytes Genetically Engineered To Target the CD19 Antigen for the Treatment of CLL Using Xcyte|[trade]| Dynabeads|[reg]| (2005) (0)
- Efficacy and Long Term Survival of Genetically Modified T Cells Targeting CD19 in a Syngeneic Immune Competent Transgenic Murine Tumor Model Is Dependent on Prior Lymphodepleting Chemotherapy. (2007) (0)
- 27 A novel strategy for generating LMPI specific T cells utilizing artificial antigen presenting cells (2003) (0)
- Optimization of globin lentiviral vector design for the treatment of β-thalassemia (2007) (0)
- A "vector drain" in US gene therapy development? (2008) (0)
- In Vitro analysis of Suicide Gene Expression and Function of 3 Suicide Gene-Prodrug Combinations In Human T Lymphocytes Further Modified to Express the CD19 Targeted 19–28z Chimeric Antigen Receptor. (2010) (0)
- 317 BLOCKADE OF TGFβ ENHANCES EFFICACY OF GENETICALLY MODIFIED HUMAN T CELLS TARGETED AGAINST PROSTATE SPECIFIC MEMBRANE ANTIGEN (2012) (0)
- T Cells Genetically Targeted to CD19 Eradicate B-ALL In a Novel Syngeneic Mouse Disease Model (2010) (0)
- Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity (2022) (0)
- Phenotype and Potent T-Cell Stimulatory Capacity Retrovirally Transduced Human Dendritic Cells Express a Normal (2013) (0)
- Abstract 4743: Genetically engineered allogeneic T Cells for BMT immunotherapy: Expression of TRAIL and PLZF selectively enhances GVT and abrogates GVHD (2011) (0)
- Advances in Brief Equal Transcription of Wild-Type and Mutant p 53 Using Bicistronic Vectors Results in the Wild-Type Phenotype 1 (2007) (0)
- In vitro expansion of CMV-specific CD4+ T-cells by artificial antigen presentation for adoptive immunotherapy in the post- transplant setting (2007) (0)
- Regulation of hematopoiesis and autoimmunity by bone marrow natural suppression (1989) (0)
- Abstract IA22: Targeting CARs to the TRAC locus enhances T-cell potency (2017) (0)
- L3MBTL1: A Polycomb Protein At the Node of Crosstalk Between the BMP4 and Hippo Signaling Pathways in Erythropoiesis. (2012) (0)
- The expanding application of lentivirus-mediated erythroid-specific gene therapy (2007) (0)
- SUV39H1 disruption imparts functional persistence to CD28-costimulated human CAR T cells (2022) (0)
- Phase I trial: CD19-Targeted CAR T-Cells in Patients with Residual CLL Following Initial Purine Analog-Based Therapy (2016) (0)
- 604. Long-Term, Erythroid-Specific Expression of Human Factor IX in Hemophilic Mice Engrafted with Lentiviral Vector-Transduced Hematopoietic Stem Cells (2005) (0)
- PROSTATE CANCER PATIENT T CELLS GENETICALLY TARGETED TO PROSTATE-SPECIFIC MEMBRANE ANTIGEN SPECIFICALLY AND EFFICIENTLY LYSE PROSTATE CANCER CELLS (1999) (0)
- 343. Repair of the Sickle-Cell Disease Mutation in Human Stem Cells Using CRISPR/Cas9 and Single-Stranded Oligodeoxynucleotides (2015) (0)
- Abstract 2748: Prostate-specific inhibition of PI3 Kinase and protein synthesis as a therapy for advanced hormone-refractory prostate cancer (2012) (0)
- Combinatorial Antigen Targeting: Ideal Anti-tumor T-Cell Responses and Sensing (2016) (0)
- Turning T cells against tumors. (2008) (0)
- 46MO Promoting functional persistence in solid tumor CAR T-cell therapy: Mesothelin-targeted CAR (M28z1XXPD1DNR) with T-cell intrinsic PD1 dominant negative receptor (2021) (0)
- LiPS-A3S, a human genomic site for robust expression of inserted transgenes. (2016) (0)
- 3152 – GENOMICS OF MULTIPLE MYELOMA DICTATES THE EXPRESSION OF CAR T-CELL TARGETS (2020) (0)
- Long-Term Survival of Dogs with Advanced Malignant Melanoma after DNA Vaccination with Xenogeneic Human Tyrosinase : A Phase I Trial 1 (2003) (0)
- 799. In Vitro and In Vivo Characterization of |[ldquo]|Second-Generation|[rdquo]| Co-Stimulatory Chimeric Antigen Receptors (CARs) Targeting the CD19 Antigen Present on B Cell Malignancies (2005) (0)
- DEVELOPMENT OF A NOVEL RETROVIRAL VECTOR BASED IL2 GENE THERAPY: DEMONSTRATION OF EFFICACY IN A RENAL CELL CARCINOMA MODEL (1999) (0)
- The 15th Annual Meeting 2009 Japan Society of Gene Therapy (2010) (0)
- CT-329 CD19-Directed Chimeric Antigen Receptor T Cell Therapy in Waldenström Macroglobulinemia: Initial Experience in Two Clinical Trials. (2022) (0)
- Artificial Antigen Presenting Cells Expand NY-ESO-1 Antigen-Specific CD8+ T Cells From Patients with Melanoma (2011) (0)
- Constitutive expression of costimulatory ligands on T cells adoptively transferred (2008) (0)
- OA02.06 Converting Tumor-Mediated PD-L1 Inhibition into CAR T-Cell Costimulation to Potentiate Thoracic Cancers Immunotherapy (2017) (0)
- Targeting a Novel Epigenetic Silencing Mechanism to Efficiently Upregulate Fetal Globin Gene Expression (2011) (0)
- Retrovirally expressed 4-1BBL dramatically increases proliferation and in vivo persistence of adoptively transferred CD19-targeted T cells, promoting complete tumor elimination. (131.16) (2010) (0)
- CARs, CCRs and iCARs: A new class of drugs for cancer immunotherapy (2014) (0)
- Engineering Converted Autologous Hematopoietic Stem Cells From Vascular Endothelial for Treatment of Hemoglobinopathies (2018) (0)
- Synergism between CAR-T Cells and a Personalized Tumor Vaccine in Hematological Malignances (2021) (0)
- Optimization of the beta-globin LCR and promoter elements for lentiviral vector-encoded the beta-globin transgene expression in beta-thalassemic mice (2008) (0)
- Mesothelin is a biomarker of tumor aggressiveness and therapy response in malignant pleural mesothelioma (MPM) (2010) (0)
- 824 High quality neoantigens are immunoedited in long-term pancreatic cancer survivors (2021) (0)
- Adoptive Therapy and Subdominant Viral Epitopes for Cytotoxic T Cells Specific for Both Dominant Prevalent HLA Alleles Permits Generation of A Panel of Artificial APCs Expressing (2009) (0)
- Abstract 3229: Biomarker validation for a rare malignancy in a mouse model (2010) (0)
- Expression of Telomerase after Retroviral Transduction Increases Lifespan of Primary Human Fibroblasts (1999) (0)
- Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency (2018) (0)
- In vitro analysis of suicide gene expression and function in human T lymphocytes transduced to express a tumor-targeted chimeric antigen receptor. (2010) (0)
- Chimeric-antigen receptor engineered human T lymphocytes from induced pluripotent stem cells for cancer therapy. (VAC11P.1003) (2014) (0)
- IN VIVO 19F NMR MEASUREMENTS OF ENHANCED CONVERSION OF 5FU TO FLUORONCJCLEOTIDES AFTER UPRT GENE TRANSDUCTION (2000) (0)
- CAR T cell therapy and the promise of T cell engineering (2014) (0)
- Abstract LB-073: Generation of novel single cell-derived engineered master pluripotent cell line as a renewable source for off-the-shelf TCR-less CAR T cells in support of first-of-kind clinical trial (2019) (0)
- Genetically Engineered Donor T Cells for BMT Immunotherapy: Expression of Trail and PLZF Selectively Enhances GVT and Abrogates GVHD (2011) (0)
- 652. Analysis of the Genomic Stability of Herpes Simplex Virus Thymidine Kinase Variants in Retrovirally Transduced Lymphocytes (2004) (0)
- Author Correction: Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy. (2022) (0)
- Tumor-Targeted Human CD4 + CD25 hi Regulatory T Cells Effectively Inhibit T Cell –mediated Rejection of CD19 + Tumors in An in Vivo xenotransplant Tumor Model (2008) (0)
- Cytolytic T + Inducing Antigen-Specific CD 8 Peptide-Pulsed Langerhans Cells for Progenitors Are More Potent Than Hemopoietic + Modified Human CD 34 Langerhans Cells Derived from Genetically (2004) (0)
- 313. Cell Type Specific Media Optimization for Clinical Retroviral Transduction Protocols (2006) (0)
- RORing T cells target CLL and MCL. (2010) (0)
- Strategies for Therapeutic Peptide Delivery by Mesenchymal Stem Cells (2008) (0)
- 558. cGMP Production of Plasmid DNA for Phase I Clinical Studies in an Academic Center (2005) (0)
- High Dose Cyclophosphamide and Pre-Treatment Disease Burden Dictate Response and Survival in a Multicenter Clinical Trial Using CD19-Specific CAR T Cells for Relapsed/Refractory B-ALL (2017) (0)
- Calibrated CAR Activation Potential Directs Alternative T Cell Fates and Therapeutic Potency (2018) (0)
- PREDICTORS FOR NEUROTOXICITY on day of infusion of chimeric antigen receptor (CAR) T cells using discovery proteomics platform (2021) (0)
- Insights into Chimeric Antigen Receptor Therapy for Chronic Lymphoblastic Leukemia. (2018) (0)
- 277. Large-Scale Generation of Genetically Modified Human CD34+ Progenitor Cell-Derived Langerhans Cells Using a Closed Culture System Suitable for Clinical Immunotherapy (2005) (0)
- Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating (2023) (0)
- Trail Over-Expression on Donor T Cells Enhances GVT and Suppresses GVHD by Inhibiting Alloreactive T Cells and Impairing Host APC Functions (2012) (0)
- Spotlight Combinatorial Antigen Targeting : Ideal [ 2 _ TD $ DIFF ] T-Cell [ 5 _ TD $ DIFF ] Sensing and [ 6 _ TD $ DIFF ] Anti-Tumor Response (2016) (0)
- TARGETED AND CELL-BASED THERAPIES (2014) (0)
- Protection of Marrow from Methotrexate Toxicity by Gene Transfer of Mutant Forms of Dihydrofolate Reductase into Hematopoietic Progenitor Cells (1998) (0)
- MicroRNA regulation directs lineage- and developmental stage-specific transgene expression in hematopoietic stem cell progeny (2008) (0)
- 799. and Characterization of “Second-Generation” Co-Stimulatory Chimeric Antigen Receptors (CARs) Targeting the CD19 Antigen Present on B Cell Malignancies (2005) (0)
- Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection (2022) (0)
- Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple (1997) (0)
- The Development of Allogeneic Tips-Derived TCR- CAR+ CD8αβ T Cells (2022) (0)
- Genomic Safe Harbors in Human iPS Cells (2011) (0)
- 132 HLA-independent T cell receptors effectively target low abundance antigens (2021) (0)
- Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Therapy (2019) (0)
- microRNA-Mediated Gene Regulation Effectively Restricts In Vivo Transgene Expression in Hematopoietic Stem Cell Progeny. (2007) (0)
- Gene therapy of haemoglobinopathy: An Italy-USA project (2010) (0)
- Targeted Integration of a CAR at a Novel Genomic Safe Harbor Directs Potent Therapeutic Outcomes (2020) (0)
- Synergism between CAR T Cells and a Personalized Tumor Vaccine in Hematological Malignances (2022) (0)
- BATF3/MYC axis drives hyper-proliferation of TET2 deficient CAR T cells (2021) (0)
- B Cell Aplasia In a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia Following Re-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen (2010) (0)
- Over-Expression Of Trail On Donor T Cells Simultaneously Ameliorates GVHD And Enhances GVT (2010) (0)
- LiPS-A3S, a human genomic site for robust expression of inserted transgenes. (2016) (0)
- Xenogeneic immunization with tyrosinase DNA vaccines: results from clinical trials in humans and dogs (2006) (0)
- Overcoming Heterogeneity in AML with a Novel or-Gated Hitcar-1XX Platform (2022) (0)
- 4. Optimization of Globin Lentiviral Vector Design for the Treatment of |[beta]|-Thalassemia (2005) (0)
- Microenvironment and Immunology In vivo Inhibition of HumanCD 19-Targeted Effector TCells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B Cell Malignancy (2011) (0)
- Optimally Stimulate CTLs in a Modified to Express Full-Length Antigen Langerhans-Type Dendritic Cells Genetically (2013) (0)
- Inhibitory chimeric antigen receptors (iCARs) limit undesirable side effects of T-cell therapies (2013) (0)
- Ongoing Activation Signals Tyrosine Phosphatase 1 and Interruption of Src Homology Domain 2-Containing Protein Ig-Like Receptors Induce Colocalization with Ligand Binding to Inhibitory Killer Cell (2004) (0)
- Genetic Engineering of Donor T Cells for BMT Immunotherapy: Expression of TRAIL and PLZF Selectively Enhances GVT and Abrogates Gvhd (2010) (0)
- Conditioning Intensity and T Cell Dose Determine Efficacy of CD19-Targeted T Cell-Mediated Tumor Eradication in an Immunocompetent Mouse Model of B-ALL. (2012) (0)
- Vector encoding the human globulin gene and use thereof in the treatment of hemoglobinopathies (2002) (0)
- Erythroid Specificity and Safety of Globin-Encoding Lentiviral Vectors (2020) (0)
- Abstract 2309: T-cell development from T cell-derived induced pluripotent stem cell (2016) (0)
- Abstract 5583: SUV39H1 disruption enhances the persistence and anti-tumor efficacy of CD28-costimulated human CAR T cells (2022) (0)
- Therapeutic Transgene Expression From Genomic Safe Harbors In Patient-Specific Induced Pluripotent Stem Cells (2010) (0)
- Donor CD19-targeted T cells exert potent graft versus lymphoma activity without GVHD (P2134) (2013) (0)
- Cas9-cleavage sequences in minimal plasmids enhance non-viral genome targeting of CARs in primary human T cells (2021) (0)
- Sensitive In Vivo Detection of Primary T Cells Expressing Membrane-Anchored Gaussia Luciferase for the Study of Adoptive T Cell Immunotherapy in Murine Models of Malignancy. (2006) (0)
- Abstract PR03: ADCLEC.syn1 CAR T cells detect combinatorial target signatures to safely prevent antigen-low AML escape (2023) (0)
- Concurrent Visualization of Trafficking and NFAT Signalling in Primary T Lymphocytes and T Cell Precursors In Vivo. (2009) (0)
- Abstract PR-003: High quality neoantigens are immunoedited in long-term pancreatic cancer survivors (2021) (0)
- Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial (2022) (0)
- Constitutive expression of co-stimulatory ligands on the adoptively transferred T lymphocytes (2008) (0)
- 763. Multimodality Imaging of Genetically Modified Lymphocytes In Vivo (2006) (0)
- Transcriptional and post transcriptional gene regulation in stem cell-based gene therapy (2008) (0)
- Senolytic CAR T cells reverse senescence-associated pathologies (2020) (0)
- Genetic Correction of Sickle Cell Disease by Co-Regulated γ-Globin Transgene Expression and ßS Interference. (2005) (0)
- 225. Activation Signals from CD19-CAR Permit NFAT-Controlled Inducible Expression of Transgenes in PBMCs (2015) (0)
- Publisher Correction: Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency (2019) (0)
- A phase I clinical trial of autologous, anti-CD19 gene targeted T cells for adults with B cell acute lymphoblastic leukemia (B-ALL). (2012) (0)
- 555. Langerhans cells modified by gene transfer of full length CMV pp65 are more potent inducers of cytolytic T lymphocytes in a CD4-dependent manner than either CMV p495 gene-modified or p495 peptide-pulsed langerhans cells (2004) (0)
- Abstract 1944:In vitroanalysis of suicide gene expression and function in human T lymphocytes transduced to express a tumor targeted chimeric antigen receptor (2010) (0)
- Neoantigen quality predicts immunoediting in survivors of pancreatic cancer (2022) (0)
- Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL (2019) (0)
- In Vivo comparison of 3 Suicide Gene-Prodrug Combinations in a Mouse Graft-Versus-Host-Disease Model (2011) (0)
This paper list is powered by the following services:
Other Resources About Michel Sadelain
What Schools Are Affiliated With Michel Sadelain?
Michel Sadelain is affiliated with the following schools:
